M. Neil Reaume, Karim Fizazi, Alan Haruo Bryce, Simon Chowdhury, Charles J. Ryan, Noemí Villanueva, Orazio Caffo, Carl G. Chakmakjian, D. Scott Ernst, Susan Feyerabend, Albert Font, Vinod Ganju, Igal Kushnir, Julio Hajdenberg, Christine Vestergaard Madsen, Jen Borrow, Valerie Ong, Peter James Ostler. "Rucaparib vs docetaxel (DTX) or second-generation androgen receptor pathway inhibitor (ARPI) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with
                    <i>BRCA</i>
                    mutations based on Eastern Cooperative Oncology Group performance status (ECOG PS) in TRITON3.." Journal of Clinical Oncology (2026). https://doi.org/10.1200/jco.2026.44.7_suppl.46